Nezglyal (leriglitazone)

Where it stands

Nezglyal (leriglitazone), held by Minoryx Therapeutics S.L., is authorised in the EU. The CHMP adopted a positive opinion on 23 July 2026, and the European Commission decision approving the product followed on 21 September 2026. The records list the therapeutic area as adrenoleukodystrophy.

The authorised indication is narrow. It covers cerebral adrenoleukodystrophy (cALD) in males with ALD aged 2 to 12 years. Patients must have non-gadolinium-enhancing (Gd-negative) lesions on brain MRI and a Neurological Functional Score (NFS) of 0 or 1. Anyone outside this age, imaging and functional profile falls outside the labelled use.

The records also show an entry for the same substance under the name Nezglyal in the EU with the status 'Refused'. They give no detail on that entry, such as its date, indication or grounds. It should not be read as a conflict with the current authorisation. Anyone relying on it should check the EMA's public documents.

Regulatory pathway and designations

The product carries three designations in the records: Orphan, Exceptional circumstances and Additional monitoring. The interval between the CHMP opinion and the Commission decision is about two months. That is in line with the usual EU process, where the Commission converts a CHMP opinion into a legally binding decision.

Exceptional circumstances is a type of marketing authorisation. It is generally used when a comprehensive data package cannot be produced, for example because the condition is very rare or collecting full data would be unethical or impracticable. Such authorisations usually come with specific obligations, and the benefit-risk balance is reassessed periodically. The records do not say what obligations apply here, so they should be read from the product information and the EPAR.

The Orphan designation reflects the rarity and seriousness of the condition. Orphan status normally brings incentives, including a period of market exclusivity. The records do not give the exclusivity terms or say how orphan status was reviewed at the time of approval.

Safety and pharmacovigilance

The records contain no safety data. They give no adverse reaction profile, contraindications, warnings or risk management plan content, so no conclusions about the product's safety can be drawn from them.

The one pharmacovigilance-relevant fact is the Additional monitoring designation. In the EU this means the product is on the list of medicines under additional monitoring, which is marked with a black inverted triangle in the product information. Healthcare professionals and patients are encouraged to report any suspected adverse reactions. The status is often applied to new active substances and to products authorised with limited data, but the records do not say why it applies here.

What to watch

Key points to follow are the specific obligations attached to the exceptional-circumstances authorisation and the timing of the periodic reassessments. These will show what further evidence is expected and whether the conditions of use stay as they are. The records do not provide this information.

Launch and access are the other open questions. The records say nothing about member-state launch timing, pricing or reimbursement, or any plans to widen the indication beyond the 2 to 12 year, Gd-negative, NFS 0–1 population. Readers should also look at the EPAR and the earlier 'Refused' entry to understand how the two outcomes relate.